conferenceboard.ca

Aligning, Foreseeing, and Optimizing HTA in Canada Pathways to Innovation and Change 2016 NHLC June 6, 2016

Dr. Gabriela Prada

Director, Health Innovation Policy

The Conference Board of Canada

prada@conferenceboard.ca

Kelly Grimes

Research Associate

The Conference Board of Canada

2

Policy Question

“What is the experience, both within Canada

and internationally, of HTA as a tool to provide

knowledge for informing decisions on the

adoption and appropriate use of

pharmaceutical products and medical devices

that benefit patients and/or wider health

system, as well as the disinvestment and

displacement of pharmaceutical products and

medical devices currently used?”

3

• Literature review

• Thirty-four, one-hour key informant interviews conducted over a three-month period (June to August, 2015)

• Three international case studies (UK, Germany, Italy – ongoing)

• Online survey of HTA organizations in Canada

Methodology

4

• Number: 31 HTA producers in Canada were invited to participate. 42 percent (13) replied.

• Mandate: generate HTA reports to support decision making (11 of 13); support public policy and resource allocation (6 of 13); train professionals in HTA methods (2 of 13).

• Team: In most organizations staff involved in HTA work have at least a masters degree as their highest qualification. Multidisciplinary teams include medical librarian/information specialists, clinicians, epidemiologists, health economists, statisticians.

Understanding HTA Producers

5

• Funding: Less than $500k (8); $1 million or more (5). Governments, grants, and hospital are the main source of these funds.

• What do they look at? Processes of care was the most common, followed by medical devices, medical procedures, combination technologies, pharmaceutical products, modes of intervention/organization of services, and laboratory testing/screening. Most respondents indicated their HTA work is used to provide evidence for technology adoption, displacement, or both.

Understanding HTA Producers (2)

6

Methods Used for Assessments

0 2 4 6 8 10 12 14

Benchmark-testing

Group judgement

Clinical trials

Post-marketing surveillance

Epidemiological/observational

Modelling

Cost or economic

Expert opinion

Meta-analysis

Systematic review

7

Perception of Functioning of the Process

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

Identification and selection of

technologies for HTA

Application of several

methodologies to conduct HTA

Dissemination and implementation of

HTA findings

Evaluation of the impact of HTA on

health policy

8

• Canada’s approach is more fragmented, especially for its size

• Separation of the HTA producer and policy-maker functions is desirable to avoid political influence

• Disinvestment/Re-assessment is a challenge in all jurisdictions

• The use of Decision Analytical Modelling (DAM) as well as other qualitative evidence that focus on the patient and caregiver perspectives allow HTA assessments to be more flexible

Learnings from other Jurisdictions

9

• The mandate for HTA producers is evolving and this

sometimes leads to a disconnect between the evidence

needed for decision making and the information provided by

HTA assessments

• Inventory management system of ‘first-in-first-out’ for priority

does not work well. Options: horizon/environmental

scanning? Focus on areas with worse mortality?

• Public and patient involvement in HTA is still very limited

• Real-world data and adaptive pathways are more often

needed

• Limited sharing across HTA producers due to use of different

frameworks, lack of databases

Challenges

10

What is Value?

11

• Support value-based healthcare systems: define outcomes, performance measures, and value and design HTA to support the measurement of these.

• Harmonization of language, framework, and products

–EUnetHTA for Canada? facilitate efficient use of resources available for HTA, create a sustainable system of HTA knowledge sharing, promote good practice in HTA methods and processes.

• Develop robust priority setting process (e.g., include criteria such as impact of health outcomes and potential costs).

• Synchronization with regulation and procurement processes.

Opportunities

12

• Develop better metrics (e.g., modeling care pathways and options of care within these pathways).

• Invest in disease registries, unique identifiers, improve information systems, and broaden access to data outside of the health system.

• Develop frameworks to support better technology management (e.g., systematic disinvestment/reassessment).

Opportunities

13

14

Closing Remarks

•Canada is a world leader in health

technology assessment.

•Value within health care is being

redefined. HTA needs to adapt to the

changing needs of health care.

•Need to clearly define the role of HTA

within VBHC and VBP.

•Patchwork system for non-drug

technologies in Canada needs to be

addressed.

•Greater collaboration with key

stakeholders is required to measure

value.

conferenceboard.ca